discontinuation2026-01-22active
Arzneimittel-Richtlinie/Anlage XII: Deutivacaftor/Tezacaftor/Vanzacaftor (Zystische Fibrose, mindestens eine Nicht-Klasse-I-Mutation, ≥ 6 Jahre) – Einstellung eines Verfahrens zur Nutzenbewertung
Open official decision page ↗
G-BA source · retrieved 2026-08-05
Decision orientation
What the G-BA did
3 cited claims
Each claim links to the official G-BA page or an exact PDF page range.
Official metadata
- Decision date
- 2026-01-22
- Effective
- 22.01.2026
- Action type
- discontinuation
- Committee
- Arzneimittel
Case context
Listed normative targets
directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V
A listed target is not treated as a new directive version unless an official version source exists.
Official document package